The latest price target for Aardvark Therapeutics (NASDAQ:AARD) was reported by B. Riley Securities on May 15, 2026. The analyst firm set a price target for $7.00 expecting AARD to rise to within 12 months (a possible 60.18% upside). 22 analyst firms have reported ratings in the last year.

The latest analyst rating for Aardvark Therapeutics (NASDAQ:AARD) was provided by B. Riley Securities, and Aardvark Therapeutics maintained their buy rating.

There is no last upgrade for Aardvark Therapeutics

The last downgrade for Aardvark Therapeutics Inc happened on May 15, 2026 when BTIG changed their price target from N/A to N/A for Aardvark Therapeutics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Aardvark Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Aardvark Therapeutics was filed on May 15, 2026 so you should expect the next rating to be made available sometime around May 15, 2027.

While ratings are subjective and will change, the latest Aardvark Therapeutics (AARD) rating was a maintained with a price target of $8.00 to $7.00. The current price Aardvark Therapeutics (AARD) is trading at is $4.37, which is out of the analyst’s predicted range.